Tags

Type your tag names separated by a space and hit enter

Oral nicotinamide protects against ultraviolet radiation-induced immunosuppression in humans.
Carcinogenesis. 2009 Jan; 30(1):101-5.C

Abstract

Cutaneous immunity, which is a key defence against the development of skin cancers, is suppressed by even small doses of ultraviolet (UV) radiation. Preventing this UV-induced immunosuppression may therefore reduce the incidence of skin cancer. Nicotinamide (vitamin B3) has immune-protective and cancer-preventive effects against UV radiation in mice, and we have shown previously that topical nicotinamide is immune protective in humans. Using the Mantoux model of skin immunity in healthy volunteers, we compared oral nicotinamide to placebo (both administered for 1 week) in a randomized, double-blinded, crossover design against the effects of solar-simulated ultraviolet (ssUV) radiation on delayed-type hypersensitivity to tuberculin purified protein derivative. Discrete areas of the back were irradiated with low doses of ssUV daily for three consecutive days. Immunosuppression, calculated as the difference in Mantoux-induced erythema of irradiated sites compared with unirradiated control sites, was determined in volunteers taking oral nicotinamide and placebo. Significant immunosuppression occurred in an UV dose-dependent manner in the presence of placebo. Oral nicotinamide, at doses of either 1500 or 500 mg daily, was well tolerated and significantly reduced UV immunosuppression with no immune effects in unirradiated skin. Oral nicotinamide is safe and inexpensive and looks promising as a chemopreventive supplement for reducing the immunosuppressive effects of sunlight.

Links

Publisher Full Text
Aggregator Full Text

Authors+Show Affiliations

Yiasemides E
Dermatology, Sydney Cancer Centre, Bosch Institute, University of Sydney at Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
Sivapirabu G
No affiliation info available
Halliday GM
No affiliation info available
Park J
No affiliation info available
Damian DL
No affiliation info available

MeSH

Administration, OralAdultCross-Over StudiesDose-Response Relationship, DrugDose-Response Relationship, RadiationDouble-Blind MethodFemaleHumansImmune ToleranceMaleMiddle AgedNiacinamidePlacebosUltraviolet Rays

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19028705

Citation

Yiasemides, Eleni, et al. "Oral Nicotinamide Protects Against Ultraviolet Radiation-induced Immunosuppression in Humans." Carcinogenesis, vol. 30, no. 1, 2009, pp. 101-5.
Yiasemides E, Sivapirabu G, Halliday GM, et al. Oral nicotinamide protects against ultraviolet radiation-induced immunosuppression in humans. Carcinogenesis. 2009;30(1):101-5.
Yiasemides, E., Sivapirabu, G., Halliday, G. M., Park, J., & Damian, D. L. (2009). Oral nicotinamide protects against ultraviolet radiation-induced immunosuppression in humans. Carcinogenesis, 30(1), 101-5. https://doi.org/10.1093/carcin/bgn248
Yiasemides E, et al. Oral Nicotinamide Protects Against Ultraviolet Radiation-induced Immunosuppression in Humans. Carcinogenesis. 2009;30(1):101-5. PubMed PMID: 19028705.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Oral nicotinamide protects against ultraviolet radiation-induced immunosuppression in humans. AU - Yiasemides,Eleni, AU - Sivapirabu,Geetha, AU - Halliday,Gary M, AU - Park,Joohong, AU - Damian,Diona L, Y1 - 2008/11/20/ PY - 2008/11/26/pubmed PY - 2009/2/13/medline PY - 2008/11/26/entrez SP - 101 EP - 5 JF - Carcinogenesis JO - Carcinogenesis VL - 30 IS - 1 N2 - Cutaneous immunity, which is a key defence against the development of skin cancers, is suppressed by even small doses of ultraviolet (UV) radiation. Preventing this UV-induced immunosuppression may therefore reduce the incidence of skin cancer. Nicotinamide (vitamin B3) has immune-protective and cancer-preventive effects against UV radiation in mice, and we have shown previously that topical nicotinamide is immune protective in humans. Using the Mantoux model of skin immunity in healthy volunteers, we compared oral nicotinamide to placebo (both administered for 1 week) in a randomized, double-blinded, crossover design against the effects of solar-simulated ultraviolet (ssUV) radiation on delayed-type hypersensitivity to tuberculin purified protein derivative. Discrete areas of the back were irradiated with low doses of ssUV daily for three consecutive days. Immunosuppression, calculated as the difference in Mantoux-induced erythema of irradiated sites compared with unirradiated control sites, was determined in volunteers taking oral nicotinamide and placebo. Significant immunosuppression occurred in an UV dose-dependent manner in the presence of placebo. Oral nicotinamide, at doses of either 1500 or 500 mg daily, was well tolerated and significantly reduced UV immunosuppression with no immune effects in unirradiated skin. Oral nicotinamide is safe and inexpensive and looks promising as a chemopreventive supplement for reducing the immunosuppressive effects of sunlight. SN - 1460-2180 UR - https://www.unboundmedicine.com/medline/citation/19028705/Oral_nicotinamide_protects_against_ultraviolet_radiation_induced_immunosuppression_in_humans_ L2 - https://academic.oup.com/carcin/article-lookup/doi/10.1093/carcin/bgn248 DB - PRIME DP - Unbound Medicine ER -